Business context and reporting period
The supplied filing is ZIOPHARM Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed March 18, 2013. It is not a 2012 Q4-only report, and the registrant named in the filing is not Alaunos Therapeutics, Inc.; investors should confirm the intended company and filing.
ZIOPHARM described itself as a development-stage biopharmaceutical company with no approved products. Its programs included palifosfamide, indibulin and darinaparsin, plus two cancer gene-therapy candidates developed under its Intrexon partnership.
Financial and operating metrics
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue, primarily collaboration funding | $0.8 million | $0.667 million |
| Research and development expense | $83.446 million | $57.083 million |
| General and administrative expense | $19.523 million | $14.984 million |
| Total operating expenses | $102.969 million | $72.067 million |
| Operating loss | $102.169 million | $71.400 million |
| Net loss | $96.132 million | $63.778 million |
| Basic and diluted loss per share | $1.22 | $0.97 |
| Net cash used in operating activities | $78.832 million | $38.835 million |
| Cash and cash equivalents at year-end | $73.306 million | $104.713 million |
| Working capital at year-end | $61.4 million | $92.7 million |
No meaningful operating margin is reported: revenue was small relative to expenses, and the company generated no product revenue. The filing reports no cash interest payments and does not identify conventional borrowings; total liabilities were $34.959 million, including $12.962 million of warrant liabilities. Contractual obligations totaled $32.129 million, including $25.162 million of CRO milestone payments, many contingent on future events.
Material changes versus the prior comparable period
- Revenue rose by $0.133 million, reflecting recognition of Solasia research and development funding.
- R&D expense increased 46% and G&A expense increased 30%. Higher clinical-trial, manufacturing, personnel and related costs drove the increases; the SCLC Phase 3 trial contributed $10.8 million of R&D expense in 2012.
- Operating cash use more than doubled, partly reflecting the larger net loss and a $5.599 million increase in prepaid expenses and other current assets, including a related-party prepayment.
- The company raised approximately $49.2 million net from a January 2012 public offering, but year-end cash still fell by $31.407 million.
- Net loss included a $6.050 million noncash gain from the change in fair value of warrant liabilities, versus a $7.583 million gain in 2011. This accounting gain reduced reported net loss but did not provide operating cash.
Outlook, risks and unusual items
- Management estimated that existing cash would fund operations only into the second half of 2013. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. No additional capital source was committed.
- For the next 12 months, management forecast approximately $123.2 million in R&D expense and $29.1 million in G&A expense. These projected expenses substantially exceed year-end cash; management said additional financing would be needed and could be dilutive or require partnering, licensing or debt.
- Management expected PICASSO 3 results in first-line metastatic soft-tissue sarcoma in the last week of March 2013. Enrollment was complete; the company said the trial’s primary endpoint had been amended to progression-free survival for full approval, with overall survival secondary. Results were uncertain and the trial could fail to support approval.
- Enrollment continued in MATISSE, a Phase 3 palifosfamide trial in metastatic small-cell lung cancer. An early safety review recommended continuing as planned; this was not an efficacy finding.
- Risks include clinical or regulatory failure, trial delays, dependence on contract manufacturers and research organizations, competition, intellectual-property challenges, reimbursement and pricing pressure, and further capital needs. Intrexon partnership costs and the 50% net-profit/revenue sharing terms are also relevant.
- The company issued 3,636,926 shares to Intrexon after starting a Phase 2 gene-therapy study. Common shares outstanding were 83.237 million at year-end and 83.704 million as of February 22, 2013.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor also gave an unqualified opinion on the financial statements and internal controls, while separately emphasizing the going-concern uncertainty.
Investor verification priorities
- Confirm that the intended filing is ZIOPHARM’s 2012 Form 10-K, rather than a filing for Alaunos Therapeutics.
- Verify current cash, cash burn, financing commitments and whether the projected second-half-2013 runway was extended.
- Check the actual PICASSO 3 and MATISSE outcomes, subsequent regulatory decisions and any changes to development plans.
- Review share-count changes, potential dilution from options and warrants, and the terms and remaining availability of Intrexon’s financing commitment.
- Validate the timing and likelihood of CRO milestone obligations and other contractual commitments; the filing’s milestone amounts are contingent, not necessarily fixed payments due on stated dates.